Skip to main content

Tesi Raymond Joseph's Form 4/A amendment

Amended

Inmune Bio, Inc. (INMB) · filed Apr 24, 2024

Accession no.
0001213900-24-035722
Filed
Apr 24, 2024, 2:08 PM ET
Trade date
Apr 19, 2024
Filing delay
5 days
Rule 10b5-1 plan
Not checked
Original filed
Apr 23, 2024

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $150.0K. It was filed 5 days after the trade.

This amendment replaces 0001213900-24-035474 (filed Apr 23, 2024).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tesi Raymond JosephCIK 0001767280Director, Officer (President and CEO), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 19, 2024Common StockPPurchaseAcquired+18,028$8.32+$149,992.961,538,726Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 19, 2024Common StockPPurchaseAcquired+18,028$0.125+$2,253.518,028Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)